Established in 2013 as a subsidiary of Luye Pharma Group, Boan Biotech is a fully integrated biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization with a focus on key therapeutic areas including oncology, metabolism, autoimmunity and ophthalmology. Boan Biotech's antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform and ADC Technology Platform. The company has developed a commercialized product and a total of 12 drug candidates, consisting of seven innovative antibody candidates and five biosimilar candidates.
Boan Biotech has expertise in the full industry chain: antibody discovery, cell line development, upstream and downstream process development, analytical and bio-analytical method development, technology transfer, pilot and commercial scale production. Outside of China, the company also pursues biopharmaceutical products development in the US and EU markets.
As of December 31, 2021, Boan Biotech has a total of 572 employees, including 213 with Master’s Degree and above. Boan Biotech has qualified professionals in complete and fully-integrated drug development process from antibody discovery to commercialization. The management team has many years of experience in drug development and project management in world-renowned pharmaceutical companies, familiar with the biopharmaceutical industry and knowledgeable in advancing professional comprehensive solutions for drug discovery and development.